. Human chorionic gonadotrophin (hCG) has been detected in the serum of 10% of women with vulval tmours (Hussa, 1987) . The renal metabolite of the a-subunit of hCG, known as P-core fragment, can be detected in the urine of women with non-trophoblastic gynaecological malignancies and has been proposed as a useful tumour marker (Cole et al., 1988; Nam et al., 1990a) . Relatively little attention has been given to vulvovaginal tumours, although elevated levels of -core were detected in four out of eight patients with vulval malignancy (Nam et al., 1990b) . Most previous studies on urinary a-core fragment have not taken into account the effect of urine concentration or the problem of cross-reactivity of most assays with lutinising hormone (LH). The latter is elevated in pen-and postmenopausal women and also has been shown to gradually decrease with increasing number of years in the postmenopausal state (Chakavarti et al., 1976) . It is women in these age groups who are most at risk of developing vulval and vaginal tumours. Previous work in our unit has pointed to the presence of a virtually identical molcule to S-core known as LH core (Iles et al., 1992) . The assay used is known to cross-react with LH core. However, the exact level of this cross-reaction is impossible to determine in the absence of purified LH core standards. To address these problems, the present study analysed urinary levels of S-core after correction for urine concentration by measurement of the urinary concentration of creatinine. Furthermore, since there is a gradual increase in urinary a-core with increasng age, the cut-off levels for separation of normal and abnormal Table I .
Each patient gave a random urine specimen which was assayed for a-core fragment by radioimmunoassay using the S504 antibody (Polyclonal Antibodies, Blaenwaen Farm, LlandysuL Dyfed, Waks) (Lee et al., 1991) . Beta-core isolated from crude urinary hCG was used for standards and tracer, the material was calibrated against the matenal isolated by Bithe et al. (1988) . The minimum detection limit of the assay as defined by the lowest concentration of P-ore which could be distinguished from the zero standard was 0.025 ng ml-'. Intra-assay variation was 2-10% and interassay variation was 2-11% for concentrations between 0.1 and 5.31 ng ml-' -core. Cross-reactivity with free P-subunit was kss than 0.7%.
Urine creatinine concentration was measured by the Jaffe method using a Monarch 200 centrifugal analyser; the result was expressed in millimoles per litre. The cut-off levels used were determined from a previous 40 -49 years (n= 81) 0.044ngmlV'mmol ' creatinine 50-59 years (n = 74) 0.064 ng ml1mmol ' creatinine 60 -69 years (n = 82) 0.088 ng ml' mmol-' creatinine 70-79 years (n=61) 0.096ngml-'mmol-' creatinine >80 years (n=65) 0.103ngml-'mmol-' creatinine All patients were followed for a minimum of 24 months and their status at this stage was recorded. The percentage survival for those with elevated Score levels was compared with those with normal Score levels using a stage corrected log-rank test and survival tables were constructed using the Kaplan-Meier method. In addition. the effect of age, stage, histological type and grade of tumour were examined using Cox's multivariate analysis. Patients with recurrent disease were analysed separately from those with initial presentation disease.
Results
Of the 50 patients in the study 19 (38%) had elevated levels of corrected core, seven of which were initial presentations and 12 were recurrent disease. Figure 1 shows the present status of the patients according to their s-ore levels. Seventeen (90%) of the patients with elevated levels had died within 2 years, six from the initial presentation group and 11 from the recurrent disease group (Table II) . Of the 31 (62%) patients with non-elevated aore levels, 20 were from the initial presentation group and 11 from the recurrent disease group. Twenty-one (68%) of these patients are still alive and comprise 15 from the initial presentation group and six from the recurrent disease group (Table II) . In six patients the process of correcting for creatinine resulted in the conversion of the -core level from normal to elevated, and of these five had died. Conversely, there were three patients were creatinine correction produced a conversion from elevated to normal, and two of these had died. Thus, with regard to prognosis, of the nine patients in whom a shift occurred, the corrected s-core status correlated with the status of the patient at 24 months in six (67%) cases.
Subdivision of the patients according to stage of disease yielded very small groups. However, for each stage of disease, if the sore was elevated, the number of patients who had died was greater than the number of those still alive (Table III) . With increasing stage of disease the proportion of deaths increased such that for stage II, III and IV disease all patients with raised -core levels had died. Conversely, for patients with stage I and II disease and normal levels of sore, 85% and 75% respectively were still alive at 24 months. However, for patients with stage III and IV disease and normal levels of a-core, only 50% and 25% respectively were still alive at 24 months.
The median value of corrected S-core for those patients who had died (n = 27) was 0.064 ng ml1' mmol ' creatinine, and that for those patients still alive (n = 23) was 0.05 ng ml-' mmol-' creatinine (P = 0.0205 using the MannWhitney test).
Figures 2 and 3 show the stage-corrected survival curves for patients tested at initial presentation and with recurrent disease. In both groups patients with elevated i-core levels had reduced survival times when compared with those with normal levels of S-core. The difference is more pronounced in the initial presentation group (log-rank chi-square = 8.52, P = 0.0035) than in the recurrent disease group (log-rank chi-square = 6.059, P = 0.0138). Cox developed recurrent disease during the study were counted in both the initial presentation and recurrent disease groups.
E iscusi
The S-core fragment of hCG in urine has been proposed as a useful marker in cases of non-trophoblastic gynaecological malignancy (Cole et al., 1988; Nam et al., 1990a) . One of the clinical criteria for such a marker is the ability to identify disease in symptomatic patients. In this respect, our earlier studies (Lee et al., 1992; Neven et al., 1993) were less promising than those of others. In the case of vulvovaginal tumours the overall sensitivity in the present study was 38% (31% at initial presentation and 47.5% for those with recurrent disease). These results are similar to those of Nam et al.
(1990b) who reported a sensitivity of 50%.
Although for gynaecological malignancies in general the sensitivity of S-core in our laboratory appears to be less than that reported by others, we have found that in cases of cervical tumours (and bladder tumours), a-core may be of considerable value as a prognostic marker (Carter et al., 1994 ; R lIes et al., unpublished data). The present report demonstrates the same phenomenon in cases of vulvovaginal tumours in that 90% of patients with elevated a-ore levels had died within 24 months of sample collection while 68% of those with normal levels were still alive after the same period.
The percentage of patients with elevated levels of S-core who had died was similar for women at initial presentation and those with recurrent disease (42% and 47.5% respectively). In patients with normal -core levels, the correlation of normal levels with survival was better for those at initial presentation than for those with recurrent diseas (48.5% and 19.5% respectively).
All patients wtih stage II, III and IV disease who had elevated 0-core levels had died within 24 months. The converse aspect (patients with normal a-core levels who are alive at 24 months) showed good correlation for stage I and II disease (85% and 75% respectively), though less so for more advanced stage disease (50% and 25% for stages III and IV).
As with cervial carcinoma, the survival curves for women at both initial presentation and recurrent disease show reduced survival if S-core levels were elevated (Figures 2 and   3 ). Furthermore, for both vulvovaginal and cervical tumours the difference between those with elevated levels and normal levels is less pronounced in patients with recurrent disease. Not unexpectedly, patients with recurrent disease have a poor prognosis, but even in these cases the S-core level has some prognostic value. Our own studies on a control population of over 400 women revealed that the urinary concentration of creatinine had more than a 40-fold variation (0.8-34mmoll-1). Furthermore, in individual subjects the -core could vary 6-fold over a 24 h period, and for these reasons it was felt necessary to correct for this. With regard to the prognostic significance of -core, the correction for urinary concentration improves the correlation between -core level and status after 24 months. Among the patients who had died there were several with normal levels of uncorrected P-core which became positive after correction for creatinine, and the converse applied to some surviving patients with elevated levels. Tlhis study further emphasi the importance of age as a potential confounding factor and allows the use of agespecific cut-off levels. Even though most women in this study were post-menopausal, there was still a 2-fold difference in 
